LONDON, UK – Mike Ballas, Global CEO of Axiom, the life sciences training and scientific engagement division of The Creative Engagement Group (TCEG), has been named EVP Healthcare for TCEG North America.
Ballas assumes this role alongside his current position of CEO of Axiom, where he will be focussed on business development opportunities and strategic partnerships, as well as supporting broader integration opportunities within The Creative Engagement Group.
Ballas’ evolved role comes at a time when the Group has expanded its operations in the US. In January, TCEG acquired New Jersey-based Forty1-Vitiello Communications Group, which provides specialist services to healthcare companies focused on enhancing the employee experience. Last year, TCEG acquired Cormis, its capability development division and Logicearth, its digital learning division. TCEG in the US will also strengthen its approach to innovation in healthcare, within areas such as artificial intelligence and gene editing.
Ballas is an existing member of the LTEN (Life Sciences Trainers & Educators Network) Advisory Council and through his new role, will drive thought leadership for TCEG within the healthcare community. He will report to Russ Lidstone, Group CEO at The Creative Engagement Group and work closely with other senior members of the management team to build on the group’s momentum.
Ballas joined Axiom eight years ago, and previously held positions at MXM Health, Novartis Oncology and Merck.
Russ Lidstone, Group CEO, The Creative Engagement Group, comments: ‘’I’m delighted that Mike is taking on this new remit. With his track record in building strong client partnerships and growing our scientific centre of excellence, no-one is better placed to support the next stage of our growth in North America.”
Mike Ballas, Global CEO of Axiom and EVP Healthcare for TCEG US says: “I’m incredibly excited to harness the power of The Creative Engagement Group North America to add additional value to our existing clients and continue to grow our presence within the pharmaceutical and biotech industry.”
